| Abstrakt: |
Potential treatment effect-modifying characteristics are, however, imbalanced between the RESORCE and CELESTIAL trial populations, including the Eastern Cooperative Oncology Group (ECOG) score, the geographic region from which they were recruited, and the duration of prior sorafenib treatment. Furthermore, standard indirect treatment comparisons assume that relative treatment effects are the same across trials and that there is no difference between trials in the distribution of baseline characteristics that might impact treatment effects. This may have introduced selection bias since clinical trial patients, per protocol, are highly selected, homogeneous, and generally healthier patients compared to real-world patients, who are more heterogenous (e.g., more comorbidities ineligible for trial enrollment), have worse performance status, and are expected to have poorer outcomes. Briefly, the anchored MAIC balanced differences in baseline characteristics that are potential treatment effect modifiers through propensity score re-weighting of patients from RESORCE to produce a patient profile matching that of CELESTIAL. [Extracted from the article] |
